Does gender have an influence on platelet function and the efficacy of oral antiplatelet therapy?

Interventional Cardiology Clinics

Volumn 1, Issue 2, 2012, Pages 223-230

  Tantry, Udaya S ^a   Navarese, Eliano P ^b   Gurbel, Paul A ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b Research Ettore Sansavini Health Science Foundation   (Italy)

Author keywords

Antiplatelet therapy; Gender difference; Platelet function; Thrombogenicity

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ORAL CONTRACEPTIVE AGENT; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; BRAIN ISCHEMIA; CORONARY ARTERY DISEASE; DRUG EFFICACY; HEART DEATH; HEART INFARCTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; STROKE; THROMBOCYTE FUNCTION; THROMBUS; TREATMENT RESPONSE;

EID: 84859578110     PISSN: 22117458     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iccl.2012.01.007     Document Type: Review

References (47)

1. Gurbel P.A., Bliden K.P., Hayes K.M., et al. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2004, 2:535-545.
2. Wright R.S., Anderson J.L., Adams C.D., et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline) A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011, 57:e215-e367.
3. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352:1293-1304.
4. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
5. Berger J.S., Roncaglioni M.C., Avanzini F., et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006, 295:306-313.
6. Baigent C., Blackwell L., Collins R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860. Antithrombotic Trialists' (ATT) Collaboration.
7. Helton T.J., Bavry A.A., Kumbhani D.J., et al. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. Am J Cardiovasc Drugs 2007, 7:289-297.
8. Berger J.S., Bhatt D.L., Cannon C.P., et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol 2009, 54:1935-1945.
9. Bhatt D.L., Fox K.A., Hacke W., et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354:1706-1717.
10. Mehta S.R., Bassand J.P., Chrolavicius S., et al. CURRENT-OASIS 7 Investigators, Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010, 363:930-942.
11. Wiviott S.D., Braunwald E., McCabe C.H., et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
12. Hochholzer W., Wiviott S.D., Antman E.M., et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation 2011, 123:2681-2689.
13. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
14. Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation 1997, 95:252-264.
15. Xing D., Nozell S., Chen Y.F., et al. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 2009, 29:289-295.
16. Vaidya D., Becker D.M., Bittner V., et al. Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data. BMJ 2011, 343:d5170.
17. Medical Research Council Risk of thromboembolic disease in women taking oral contraceptives. BMJ 1967, 2:355-359.
18. McGregor L., Morazain R., Renaud S. Effect of different concentrations of an oral contraceptive and of pregnancy on platelet functions and platelet phospholipids fatty acid composition in rats. Haemostasis and thrombosis 1979, vol. 15:565-570. Academic Press Inc, New York. G.G. Serneri, C.M. Prentice (Eds.).
19. Uzunova A., Ramey E., Ramwell P.W. Effect of testosterone, sex and age on experimentally induced arterial thrombosis. Nature 1976, 261:712-713.
20. Johnson M., Ramey E., Ramwell P.W. Sex and age differences in human platelet aggregation. Nature 1975, 253:355-357.
21. Emms H., Lewis G.P. Sex and hormonal influences on platelet sensitivity and coagulation in the rat. Br J Pharmacol 1985, 86:557-563.
22. Emms H., Lewis G.P. The effect of synthetic ovarian hormones on an in vivo model of thrombosis in the rat. Br J Pharmacol 1985, 84:243-248.
23. Johnson M., Ramey E., Ramwell P.W. Androgen-mediated sensitivity in platelet aggregation. Am J Physiol 1977, 232:H381-H385.
24. Leng X.H., Hong S.Y., Larrucea S., et al. Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males. Arterioscler Thromb Vasc Biol 2004, 24:376-381.
25. Higashiura K., Mathur R.S., Halushka P.V. Gender-related differences in androgen regulation of thromboxane A2 receptors in rat aortic smooth-muscle cells. J Cardiovasc Pharmacol 1997, 29:311-315.
26. Ajayi A.A., Hercule H., Cory J., et al. Gender difference in vascular and platelet reactivity to thromboxane A(2)-mimetic U46619 and to endothelial dependent vasodilation in Zucker fatty (hypertensive, hyperinsulinemic) diabetic rats. Diabetes Res Clin Pract 2003, 59:11-24.
27. McGill D.A., Ardlie N.G. Abnormal platelet reactivity in men with premature coronary heart disease. Coron Artery Dis 1994, 5:889-900.
28. Kurrelmeyer K., Becker L., Becker D., et al. Platelet hyperreactivity in women from families with premature atherosclerosis. J Am Med Womens Assoc 2003, 58:272-277.
29. Yee D.L., Sun C.W., Bergeron A.L., et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005, 106:2723-2729.
30. Santimone I., Di Castelnuovo A., De Curtis A., MOLI-SANI Project Investigators, et al. White blood cell count, sex and age are major determinants of heterogeneity of platelet indices in an adult general population: results from the MOLI-SANI project. Haematologica 2011, 96:1180-1188.
31. Meade T.W., Vickers M.V., Thompson S.G., et al. Epidemiological characteristics of platelet aggregability. Br Med J (Clin Res Ed) 1985, 290:428-432.
32. Becker D.M., Segal J., Vaidya D., et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006, 295:1420-1427.
33. Faraday N., Goldschmidt-Clermont P.J., Bray P.F. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost 1997, 77:748-754.
34. Egan K.M., Lawson J.A., Fries S., et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004, 306:1954-1957.
35. Bar J., Lahav J., Hod M., et al. Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17beta-estradiol and medroxyprogesterone acetate in postmenopausal women. Thromb Haemost 2000, 84:695-700.
36. Jayachandran M., Miller V.M. Human platelets contain estrogen receptor alpha, caveolin-1 and estrogen receptor associated proteins. Platelets 2003, 14:75-81.
37. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801-1811.
38. Harrison M.J., Weisblatt E. A sex difference in the effect of aspirin on " spontaneous" platelet aggregation in whole blood. Thromb Haemost 1983, 50:773-774.
39. Spranger M., Aspey B.S., Harrison M.J. Sex difference in antithrombotic effect of aspirin. Stroke 1989, 20:34-37.
40. Escolar G., Bastida E., Garrido M., et al. Sex-related differences in the effects of aspirin on the interaction of platelets with subendothelium. Thromb Res 1986, 44:837-847.
41. Kelton J.G., Hirsh J., Carter C.J., et al. Sex differences in the antithrombotic effects of aspirin. Blood 1978, 52:1073-1076.
42. Qayyum R., Becker D.M., Yanek L.R., et al. Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol 2008, 101:1359-1363.
43. Ivandic B.T., Giannitsis E., Schlick P., et al. Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin Chem 2007, 53:614-619.
44. Xie H.G. Direct evidence for the higher frequency of CYP2C19 allelic heterozygotes in Chinese subjects than in white subjects. Clin Pharmacol Ther 1997, 62:691-692.
45. Ramsjo M., Aklillu E., Bohman L., et al. CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol 2010, 66:871-877.
46. Shuldiner A.R., O'Connell J.R., Bliden K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302:849-857.
47. Gurbel P.A., Bliden K.P., Cohen E., et al. Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. Blood Coagul Fibrinolysis 2008, 19:268-275.